Focus on zavegepant: the first intranasal third-generation gepant.
Pain Manag
; 12(8): 879-885, 2022 Nov.
Article
en En
| MEDLINE
| ID: mdl-36189708
Migraine is the leading cause of years lived with disability in people under 50 and the frequent chronicity of the disease increases its global burden. Recent research prompted the discovery of novel modulators fundamentally involved in the pathogenesis and chronicity of migraine, such as calcitonin gene-related peptide (CGRP). This induced the development of new drugs able to antagonize the CGRP receptor, called gepants. The purpose of the present study was to offer a monograph on the novel, third-generation gepant, zavegepant. It is the first gepant to be administered via the intranasal route. Here, the authors report the available data on the efficacy and safety of zavegepant and investigate future perspectives.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Antagonistas del Receptor Peptídico Relacionado con el Gen de la Calcitonina
/
Trastornos Migrañosos
Límite:
Humans
Idioma:
En
Revista:
Pain Manag
Año:
2022
Tipo del documento:
Article
País de afiliación:
Italia
Pais de publicación:
Reino Unido